Serious adverse events(4 months) · children and young people with JIA
Methotrexate showed no clear difference in serious adverse events(4 months) compared with alternative disease‐modifying antirheumatic drugs (low certainty).
1 finding from 1 review
Serious adverse events(up to 6 months) · children and young people with JIA
Methotrexate showed no clear difference in serious adverse events(up to 6 months) compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Methotrexate showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with primary CNS lymphoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs · psoriatic arthritis
Methotrexate showed no clear difference in serious adverse events (SAEs) assessed by number of events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events (leflunomide) assessed by number of events · psoriatic arthritis
1 finding from 1 review
Serious adverse events (ciclosporin A) assessed by number of events · psoriatic arthritis
1 finding from 1 review
Serious adverse events (Schröder 2006) · adult patients with refractory Crohn's disease
It is very uncertain whether methotrexate + infliximab changes serious adverse events (Schröder 2006) compared with infliximab alone (very low certainty).
1 finding from 1 review
Serious adverse events Analysis 11.2 · patients with rheumatoid arthritis
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in serious adverse events Analysis 11.2 compared with methotrexate monotherapy (moderate certainty).
1 finding from 1 review
Serious adverse events(12 months) · children and young people with JIA
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Serious adverse events (proportion) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether 6‐Mercaptopurine changes serious adverse events compared with methotrexate (very low certainty).
1 finding from 1 review
Serious adverse events* · adults with renal vasculitis for maintenance therapy
Leflunomide showed no clear difference in serious adverse events* compared with methotrexate (low certainty).
1 finding from 1 review
Intervention not reported
Serious Adverse Events · patients with rheumatoid arthritis
The intervention showed no clear difference in serious Adverse Events (moderate certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review